Edmp Inc. lifted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,023 shares of the biopharmaceutical company’s stock after buying an additional 580 shares during the period. Pfizer comprises 3.3% of Edmp Inc.’s investment portfolio, making the stock its 10th largest position. Edmp Inc.’s holdings in Pfizer were worth $3,528,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Boston Partners raised its holdings in shares of Pfizer by 7.3% during the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after buying an additional 1,649,801 shares in the last quarter. Bank of Nova Scotia increased its stake in Pfizer by 325.9% in the 1st quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after purchasing an additional 1,480,258 shares during the period. Fisher Asset Management LLC increased its stake in Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after purchasing an additional 1,275,832 shares during the period. State of Tennessee Treasury Department increased its stake in Pfizer by 22.7% in the 1st quarter. State of Tennessee Treasury Department now owns 4,891,784 shares of the biopharmaceutical company’s stock worth $167,348,000 after purchasing an additional 904,413 shares during the period. Finally, Achmea Investment Management B.V. purchased a new position in Pfizer in the 1st quarter worth approximately $25,502,000. 68.99% of the stock is currently owned by institutional investors.

Pfizer, Inc. (NYSE PFE) remained flat at $36.05 during midday trading on Monday. 3,641,782 shares of the company traded hands. The firm has a 50 day moving average price of $34.72 and a 200 day moving average price of $33.69. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.24. The stock has a market cap of $214.40 billion, a P/E ratio of 26.37 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. On average, equities research analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.55%. Pfizer’s payout ratio is currently 94.12%.

WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/09/edmp-inc-increases-position-in-pfizer-inc-pfe.html.

A number of brokerages have commented on PFE. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a research note on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $38.21.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock worth $15,813,961 over the last 90 days. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.